Exercise's protective effect against colorectal cancer isn't universal—your genetic makeup determines whether you'll benefit. This finding challenges the one-size-fits-all approach to cancer prevention recommendations and points toward personalized medicine strategies based on individual genetic profiles.
Genome-wide analysis of over 42,000 participants revealed that a specific genetic variant, rs4779584 located near the GREM1 and SCG5 genes, acts as a molecular switch for exercise benefits. People carrying two copies of the C allele (CC genotype) experienced a robust 20% reduction in colorectal cancer risk when physically active, defined as 8.75 MET-hours per week or more. However, individuals with CT or TT genotypes showed no significant cancer risk reduction from the same level of physical activity. A second variant near the KCNG1 gene showed similar interaction patterns when activity was measured in quartiles.
This gene-environment interaction represents a significant advance in understanding colorectal cancer prevention. The GREM1 gene encodes a protein involved in bone morphogenetic protein signaling, which regulates cell growth and differentiation in the colon. The finding suggests that genetic variants may influence how exercise-induced metabolic and inflammatory changes translate into cancer protection. For precision medicine, this opens possibilities for genetic testing to identify individuals who would benefit most from exercise interventions. However, the research represents just one population study, and the mechanisms linking these variants to exercise response remain unclear. Until genetic screening becomes routine, the broad cancer-protective benefits of physical activity still support universal exercise recommendations, though future guidelines may incorporate genetic risk stratification.